Progressive arterial occlusive disease (PAOD) and pulmonary arterial hypertension (PAH) as new adverse events of second generation TKIs in CML treatment: who's afraid of the big bad wolf?

Leuk Res. 2012 Jul;36(7):813-4. doi: 10.1016/j.leukres.2012.03.010. Epub 2012 Apr 5.

Authors

Massimo Breccia¹, Fabio Efficace, Giuliana Alimena

Affiliation

¹ Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy. breccia@bce.uniroma1.it

PMID: 22483067
DOI: 10.1016/j.leukres.2012.03.010

No abstract available

MeSH terms

Aged
Antineoplastic Agents / adverse effects
Antineoplastic Agents / therapeutic use
Arterial Occlusive Diseases / chemically induced*
Arterial Occlusive Diseases / epidemiology
Arterial Occlusive Diseases / etiology
Clinical Trials as Topic / statistics & numerical data
Disease Progression
Drug-Related Side Effects and Adverse Reactions / epidemiology
Drug-Related Side Effects and Adverse Reactions / psychology
Familial Primary Pulmonary Hypertension
Fear / physiology
Humans
Hypertension, Pulmonary / chemically induced*
Hypertension, Pulmonary / epidemiology
Hypertension, Pulmonary / etiology
Incidence
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / epidemiology
Middle Aged
Protein Kinase Inhibitors / adverse effects*
Protein Kinase Inhibitors / classification
Protein Kinase Inhibitors / therapeutic use*
Protein-Tyrosine Kinases / antagonists & inhibitors
Pulmonary Artery / drug effects
Pulmonary Artery / pathology*
Risk Assessment

Substances

Antineoplastic Agents
Protein Kinase Inhibitors
Protein-Tyrosine Kinases